Drugs / CordSTEM-DD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04530071 | Sep 2020 → Apr 2023 | chronic pain syndrome, lumbar disk degenerative disorder | CHABiotech CO., Ltd | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-09-26 | CHABiotech CO., Ltd | Results 차바이오텍, CordSTEM-DD 임상 1·2a상 결과 발표 chabio.com ↗
결과보고서에 따르면 1차 지표인 안전성 평가에서 용량제한 독성(Dose Limiting Toxicity, DLT)이 확인되지 않았고, 임상시험의약품과 관련한 Grade 4,5의 중대한 이상약물반응이 보고되지 않아 안전성과 내약성이 확인됐다. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-09-26 | CHABiotech CO., Ltd | 차바이오텍, CordSTEM-DD 임상 1·2a상 결과 발표 chabio.com ↗ |
| 2023-04-20 | CHABiotech CO., Ltd | 퇴행성 요추 추간판으로 인한 만성 요통 세포치료제 ‘CordSTEM-DD’ 임상 1/2a상 종료 chabio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CordSTEM-DD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04530071 ↗ |
| Modality | Cell therapy | “an allogeneic umbilical cord-derived mesenchymal stem cell” NCT04530071 ↗ |